SARS-CoV-2 Spike Protein RBD (Omicron B.1.1.529 Variant)

Our renowned principal Abbexa, has recently launched a range of SARS-CoV-2 Spike Protein RBD (Omicron B.1.1.529 Variant).Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Spike Protein Receptor-Binding Domain (RBD) is a recombinant protein expressed in Mammalian cells. The SARS-CoV-2 Spike Protein (S protein) is a viral protein that allows the entry of SARS-CoV-2 into human cells. 

The protein forms trimers on the viral capsid and binds to human Angiotensin Converting Enzyme 2 (ACE2) located on the cell surface. The protein has a cleavage site between the Spike Protein and S2 subunits that is targeted by the human enzyme Furin, and it may also cause the development of a syncytium (cell fusion). Antibodies to S protein can prevent viral entry as well as target the virus for further immune action. The B.1.1.529 (Omicron) variant was identified in South Africa in November 2021. It possess a large number of mutations (G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493K, G496S, Q498R, N501Y, Y505H) which appear to increase the risk of reinfection compared to other variants of concern.